(Q36580628)

15 August 2017

1 reference

title

Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence (English)

1 reference

15 August 2017

1 reference

Desreumaux P

1

1 reference

15 August 2017

Ghosh S

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Alimentary Pharmacology & Therapeutics

15 August 2017

published in

1 reference

15 August 2017

volume

24 Suppl 1

1 reference

15 August 2017

page(s)

2-9

1 reference

An experiment to determine the active therapeutic moiety of sulphasalazine

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

Peroxynitrite-induced apoptosis in human intestinal epithelial cells is attenuated by mesalamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

Effects of mesalamine on the hsp72 stress response in rat IEC-18 intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

APC-dependent suppression of colon carcinogenesis by PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

Regulation of peroxisome proliferator-activated receptor-gamma-mediated gene expression. A new mechanism of action for high density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

The nuclear receptor superfamily: the second decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

Phosphorylation of transcriptional coactivator peroxisome proliferator-activated receptor (PPAR)-binding protein (PBP). Stimulation of transcriptional regulation by mitogen-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

Nitration of PPARgamma inhibits ligand-dependent translocation into the nucleus in a macrophage-like cell line, RAW 264

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

Review article: colorectal carcinoma and inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

Risk of cancer in inflammatory bowel disease (IBD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

Repression of beta-catenin function in malignant cells by nonsteroidal antiinflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

Nitric oxide-releasing mesalamine: potential utility for treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03069.X

10.1111/J.1365-2036.2006.03069.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference